150 related articles for article (PubMed ID: 23321168)
1. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
Lin YL; Li ZG; He ZK; Guan TY; Ma JG
J Int Med Res; 2012; 40(6):2117-23. PubMed ID: 23321168
[TBL] [Abstract][Full Text] [Related]
2. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
3. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
4. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.
Lin YL; Li ZG; Guan TY
Urol Int; 2013; 90(2):219-24. PubMed ID: 23171734
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.
Lin YL; Ma JH; Luo XL; Guan TY; Li ZG
J Int Med Res; 2013 Feb; 41(1):48-54. PubMed ID: 23569129
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer.
Ma JG; He ZK; Ma JH; Li WP; Sun G
J Int Med Res; 2013 Feb; 41(1):38-47. PubMed ID: 23569128
[TBL] [Abstract][Full Text] [Related]
11. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
Yu J; Cheng YY; Tao Q; Cheung KF; Lam CN; Geng H; Tian LW; Wong YP; Tong JH; Ying JM; Jin H; To KF; Chan FK; Sung JJ
Gastroenterology; 2009 Feb; 136(2):640-51.e1. PubMed ID: 19084528
[TBL] [Abstract][Full Text] [Related]
12. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.
Lin YL; Liu XQ; Li WP; Sun G; Zhang CT
Int Urol Nephrol; 2012 Feb; 44(1):111-7. PubMed ID: 21516472
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
Wang L; Xie PG; Lin YL; Ma JG; Li WP
Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
[TBL] [Abstract][Full Text] [Related]
17. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
[TBL] [Abstract][Full Text] [Related]
18. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
19. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
20. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Heitzer E; Artl M; Filipits M; Resel M; Graf R; Weißenbacher B; Lax S; Gnant M; Wrba F; Greil R; Dietze O; Hofbauer F; Böhm G; Höfler G; Samonigg H; Schaberl-Moser R; Balic M; Dandachi N
Mod Pathol; 2014 Jun; 27(6):906-15. PubMed ID: 24309322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]